nach oben

Erschienen in:

31.05.2022 | Imaging Informatics and Artificial Intelligence

Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer

verfasst von: Lan He, Zhen-Hui Li, Li-Xu Yan, Xin Chen, Sebastian Sanduleanu, Wen-Zhao Zhong, Phillippe Lambin, Zhao-Xiang Ye, Ying-Shi Sun, Yu-Lin Liu, Jin-Rong Qu, Lin Wu, Chang-Ling Tu, Madeleine Scrivener, Thierry Pieters, Emmanuel Coche, Qian Yang, Mei Yang, Chang-Hong Liang, Yan-Qi Huang, Zai-Yi Liu

Erschienen in: European Radiology | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To date, there are no data on the noninvasive surrogate of intratumoural immune status that could be prognostic of survival outcomes in non-small cell lung cancer (NSCLC). We aimed to develop and validate the immune ecosystem diversity index (iEDI), an imaging biomarker, to indicate the intratumoural immune status in NSCLC. We further investigated the clinical relevance of the biomarker for survival prediction.

Methods

In this retrospective study, two independent NSCLC cohorts (Resec1, n = 149; Resec2, n = 97) were included to develop and validate the iEDI to classify the intratumoural immune status. Paraffin-embedded resected specimens in Resec1 and Resec2 were stained by immunohistochemistry, and the density percentiles of CD3⁺, CD4⁺, and CD8⁺ T cells to all cells were quantified to estimate intratumoural immune status. Then, EDI features were extracted using preoperative computed tomography to develop an imaging biomarker, called iEDI, to determine the immune status. The prognostic value of iEDI was investigated on NSCLC patients receiving surgical resection (Resec1; Resec2; internal cohort Resec3, n = 419; external cohort Resec4, n = 96; and TCIA cohort Resec5, n = 55).

Results

iEDI successfully classified immune status in Resec1 (AUC 0.771, 95% confidence interval [CI] 0.759–0.783; and 0.770 through internal validation) and Resec2 (0.669, 0.647–0.691). Patients with higher iEDI-score had longer overall survival (OS) in Resec3 (unadjusted hazard ratio 0.335, 95%CI 0.206–0.546, p < 0.001), Resec4 (0.199, 0.040–1.000, p < 0.001), and TCIA (0.303, 0.098–0.944, p = 0.001).

Conclusions

iEDI is a non-invasive surrogate of intratumoural immune status and prognostic of OS for NSCLC patients receiving surgical resection.

Key Points

• Decoding tumour immune microenvironment enables advanced biomarkers identification.

• Immune ecosystem diversity index characterises intratumoural immune status noninvasively.

• Immune ecosystem diversity index is prognostic for NSCLC patients.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30CrossRefPubMed

Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York

Donnem T, Hald SM, Paulsen EE et al (2015) Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 21(11):2635–2643CrossRefPubMed

Donnem T, Kilvaer TK, Andersen S et al (2016) Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol 27(2):225–232CrossRefPubMed

Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346–354CrossRefPubMed

Natrajan R, Sailem H, Mardakheh FK et al (2016) Microenvironmental heterogeneity parallels breast cancer progression: a histology-genomic integration analysis. PLoS Med 13(2):e1001961CrossRefPubMedPubMedCentral

Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumour immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–350

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cance 12(4):298–306CrossRef

Bremnes RM, Busund LT, Kilvaer TL et al (2016) The role of tumour-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol 11(6):789–800

10.

Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232(2):199–209CrossRefPubMed

11.

Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19(9):1180–1191CrossRefPubMed

12.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128CrossRefPubMedPubMedCentral

13.

Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571CrossRefPubMedPubMedCentral

14.

Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567CrossRefPubMedPubMedCentral

15.

Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3(11):1529–1537CrossRefPubMedPubMedCentral

16.

Steele KE, Tan TH, Korn R et al (2018) Measuring multiple parameters of CD8+ tumour-infiltrating lymphocytes in human cancers by image analysis. J Immunother Cancer 6(1):20

17.

Yan X, Jiao SC, Zhang GQ, Guan Y, Wang JL (2017) Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer. Cancer Gene Ther 24(2):57–63CrossRefPubMedPubMedCentral

18.

Domagala-Kulawik J, Raniszewska A (2017) How to evaluate the immune status of lung cancer patients before immunotherapy. Breathe 13(4):291–296CrossRefPubMedPubMedCentral

19.

Grossmann P, Stringfield O, El-Hachem N et al (2017) Defining the biological basis of radiomic phenotypes in lung cancer. Elife 6:e23421CrossRefPubMedPubMedCentral

20.

Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRefPubMed

21.

National Comprehensive Cancer Network (NCCN) (2014) NCCN clinical practice guidelines in oncology: non-small cell lung cancer, V4. 2014. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed August 15, 2014.

22.

Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337–344CrossRefPubMed

23.

Fraley C, Raftery AE (2002) Model-based clustering, discriminant analysis, and density estimation. Journal of the American Statistical Association 97(458):611–631CrossRef

24.

El Naqa I, Ten Haken RK (2018) Can radiomics personalise immunotherapy? Lancet Oncol 19(9):1138–1139CrossRefPubMed

25.

Maley CC, Koelble K, Natrajan R, Aktipis A, Yuan Y (2015) An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res 17(1):131CrossRefPubMedPubMedCentral

26.

Maley CC, Aktipis A, Graham TA et al (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17(10):605–619CrossRefPubMedPubMedCentral

27.

Pienta KJ, McGregor N, Axelrod R, Axelrod DE (2008) Ecological therapy for cancer: defining tumours using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 1(4):158–164

28.

Merlo LM, Pepper JW, Reid BJ, Maley CC (2016) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6(12):924–935CrossRef

29.

Zwanenburg A, Vallières M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328–338

30.

Tang C, Hobbs B, Amer A et al (2018) Development of an immune-pathology informed radiomics model for non-small cell lung cancer. Sci Rep 8(1):1922CrossRefPubMedPubMedCentral

31.

Aerts HJ (2016) The Potential of Radiomic-Based Phenotyping in Precision Medicine: a Review. JAMA Oncol 2(12):1636–1642CrossRefPubMed

32.

Jiang Y, Wang H, Wu J et al (2020) Noninvasive imaging evaluation of tumour immune microenvironment to predict outcomes in gastric cancer. Ann Oncol 31(6):760–768

33.

Rakaee M, Kilvaer TK, Dalen SM et al (2018) Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer. Hum Pathol 79:188–198

34.

Ogino S, Giannakis M (2018) Immunoscore for (colorectal) cancer precision medicine. Lancet 391(10135):2084–2086CrossRefPubMedPubMedCentral

35.

Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271CrossRefPubMed

36.

Ferris RL, Galon J (2016) Additional support for the introduction of immune cell quantification in colorectal cancer classification. J Natl Cancer Inst 108(8):djw033.

37.

Ascierto PA, Capone M, Urba WJ et al (2013) The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 11:54CrossRefPubMedPubMedCentral

Titel: Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer
verfasst von: Lan He
Zhen-Hui Li
Li-Xu Yan
Xin Chen
Sebastian Sanduleanu
Wen-Zhao Zhong
Phillippe Lambin
Zhao-Xiang Ye
Ying-Shi Sun
Yu-Lin Liu
Jin-Rong Qu
Lin Wu
Chang-Ling Tu
Madeleine Scrivener
Thierry Pieters
Emmanuel Coche
Qian Yang
Mei Yang
Chang-Hong Liang
Yan-Qi Huang
Zai-Yi Liu
Publikationsdatum: 31.05.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 12/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-022-08873-6

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Prognostic value of ASPECTS on post-treatment diffusion-weighted imaging for acute ischemic stroke patients after endovascular thrombectomy: comparison with infarction volume

MRI changes in diaphragmatic motion and curvature in Pompe disease over time

Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status

Association between visual emphysema and lung nodules on low-dose CT scan in a Chinese Lung Cancer Screening Program (Nelcin-B3)

Virtual conferences: results of an international survey on radiologist preferences and perspectives

Predicting ultrasound-guided thermal ablation benefit in primary hyperparathyroidism

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie